<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 08 Mar 2021 13:39:00 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>中国ADC技术全梳理</title><link>https://mp.weixin.qq.com/s/l_gusNEy6FQQc4IpjuesWg</link><description></description><content:encoded><![CDATA[中国ADC技术全梳理]]></content:encoded><pubDate>Mon, 08 Mar 2021 11:32:12 +0800</pubDate></item><item><title>Moderna启动南非突变株新冠疫苗的临床试验</title><link>https://mp.weixin.qq.com/s/7Jl9mSRdpATtuA5R_5zUyQ</link><description></description><content:encoded><![CDATA[Moderna启动南非突变株新冠疫苗的临床试验]]></content:encoded><pubDate>Sun, 07 Mar 2021 07:55:39 +0800</pubDate></item><item><title>肿瘤免疫治疗的炎症性副作用</title><link>https://mp.weixin.qq.com/s/UmDorgB-0M0CQulLvzRA2Q</link><description></description><content:encoded><![CDATA[肿瘤免疫治疗的炎症性副作用]]></content:encoded><pubDate>Sat, 06 Mar 2021 14:34:34 +0800</pubDate></item><item><title>国内第2家：百奥赛图申报CD40抗体</title><link>https://mp.weixin.qq.com/s/N5jtL6T2hxJ7BlrasScmHQ</link><description></description><content:encoded><![CDATA[国内第2家：百奥赛图申报CD40抗体]]></content:encoded><pubDate>Sat, 06 Mar 2021 14:34:34 +0800</pubDate></item><item><title>双抗：靶向肿瘤新抗原</title><link>https://mp.weixin.qq.com/s/x1rl305jarNVsLMvfzSutA</link><description></description><content:encoded><![CDATA[双抗：靶向肿瘤新抗原]]></content:encoded><pubDate>Fri, 05 Mar 2021 22:33:50 +0800</pubDate></item><item><title>信达生物申报第6款双抗：IBI321</title><link>https://mp.weixin.qq.com/s/Vra1FK8sbIZnitlTNeVN3Q</link><description></description><content:encoded><![CDATA[信达生物申报第6款双抗：IBI321]]></content:encoded><pubDate>Thu, 04 Mar 2021 15:11:18 +0800</pubDate></item><item><title>乐普生物申报溶瘤病毒：CG0070</title><link>https://mp.weixin.qq.com/s/feqCmVv9-ABJVgDjW9CLMg</link><description></description><content:encoded><![CDATA[乐普生物申报溶瘤病毒：CG0070]]></content:encoded><pubDate>Thu, 04 Mar 2021 15:11:18 +0800</pubDate></item><item><title>挑战K药一线NSCLC地位：百济神州启动PD-1+TIGIT的国际多中心三期临床</title><link>https://mp.weixin.qq.com/s/5pSMMFXxBMiAdFxgdMtsBQ</link><description></description><content:encoded><![CDATA[挑战K药一线NSCLC地位：百济神州启动PD-1+TIGIT的国际多中心三期临床]]></content:encoded><pubDate>Wed, 03 Mar 2021 11:13:36 +0800</pubDate></item><item><title>以色列疫苗接种超9成，非洲多地至今无疫苗——全球新冠疫苗接种情况分析</title><link>https://mp.weixin.qq.com/s/j8gTdKQKuEfs0GTN-4qxtw</link><description></description><content:encoded><![CDATA[以色列疫苗接种超9成，非洲多地至今无疫苗——全球新冠疫苗接种情况分析]]></content:encoded><pubDate>Tue, 02 Mar 2021 07:23:14 +0800</pubDate></item><item><title>强生新冠疫苗获FDA批准，仅需单针注射</title><link>https://mp.weixin.qq.com/s/iZ5ePtHXjiRyGE_cw3mKzA</link><description></description><content:encoded><![CDATA[强生新冠疫苗获FDA批准，仅需单针注射]]></content:encoded><pubDate>Sun, 28 Feb 2021 09:12:22 +0800</pubDate></item><item><title>国内首个：鲁南制药申报BCMA/CD3双抗</title><link>https://mp.weixin.qq.com/s/USmAQEQtBbk7O6zHR-LrWg</link><description></description><content:encoded><![CDATA[国内首个：鲁南制药申报BCMA/CD3双抗]]></content:encoded><pubDate>Sat, 27 Feb 2021 10:44:13 +0800</pubDate></item><item><title>尚健生物研发BCMA ADC药物</title><link>https://mp.weixin.qq.com/s/M_QUpP9M-pERBJxAlAgsQA</link><description></description><content:encoded><![CDATA[尚健生物研发BCMA ADC药物]]></content:encoded><pubDate>Fri, 26 Feb 2021 07:24:53 +0800</pubDate></item><item><title>百济神州2020：PD-1销售额10亿元，研发费用83亿元</title><link>https://mp.weixin.qq.com/s/PeKcvJIHQ22AIPNV6eQxVw</link><description></description><content:encoded><![CDATA[百济神州2020：PD-1销售额10亿元，研发费用83亿元]]></content:encoded><pubDate>Fri, 26 Feb 2021 07:24:53 +0800</pubDate></item></channel></rss>